NTRK1 and neoplasm: Lenvatinib, confirmed as an inhibitor of VEGF receptors 1–3, FGF receptors 1–4, platelet-derived growth factor (PDGF) receptor α, KIT, and RET, selectively inhibits receptor tyrosine kinases involved in tumor growth and angiogenesis (19, 20).